Drug Profile
Anti-CD4 monoclonal antibody KT6
Latest Information Update: 04 Jul 1996
Price :
$50
*
At a glance
- Originator University of Oxford
- Class Antineoplastics; Antirheumatics; Antivirals; Monoclonal antibodies
- Mechanism of Action CD4 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 31 May 1996 No-Development-Reported for Transplant rejection in United Kingdom (Unknown route)